Literature DB >> 12048285

The merits of monitoring: should we follow all our rheumatoid arthritis patients in daily practice?

J Fransen, G Stucki, P van Riel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12048285     DOI： 10.1093/rheumatology/41.6.601

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  6 in total

1.  Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial.

Authors:  J Fransen; H Bernelot Moens; I Speyer; P L C M van Riel
Journal:  Ann Rheum Dis       Date:  2005-04-13       Impact factor: 19.103

2.  Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit.

Authors:  P Sidiropoulos; G Bertsias; H D Kritikos; H Kouroumali; K Voudouris; D T Boumpas
Journal:  Ann Rheum Dis       Date:  2004-02       Impact factor: 19.103

3.  Evaluation of disease activity in rheumatoid arthritis by Routine Assessment of Patient Index Data 3 (RAPID3) and its correlation to Disease Activity Score 28 (DAS28) and Clinical Disease Activity Index (CDAI): an Indian experience.

Authors:  H Singh; V Gupta; S Ray; H Kumar; P Talapatra; M Kaur; S Kumar; S Arya; R Mathur; N Ghangas
Journal:  Clin Rheumatol       Date:  2012-09-15       Impact factor: 2.980

4.  Measures of rheumatoid arthritis disease activity in Australian clinical practice.

Authors:  Andrew Taylor; Hanish Bagga
Journal:  ISRN Rheumatol       Date:  2011-05-04

5.  DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment.

Authors:  Bert Vander Cruyssen; Stijn Van Looy; Bart Wyns; Rene Westhovens; Patrick Durez; Filip Van den Bosch; Eric M Veys; Herman Mielants; Luc De Clerck; Anne Peretz; Michel Malaise; Leon Verbruggen; Nathan Vastesaeger; Anja Geldhof; Luc Boullart; Filip De Keyser
Journal:  Arthritis Res Ther       Date:  2005-07-08       Impact factor: 5.156

6.  Real World Experience of Disease Activity in Patients With Rheumatoid Arthritis and Response to Treatment With Varios Biologic DMARDs.

Authors:  Vladimira Boyadzhieva; Nikolay Stoilov; Mariana Ivanova; Guenka Petrova; Rumen Stoilov
Journal:  Front Pharmacol       Date:  2018-11-20       Impact factor: 5.810
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.